Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Jane Street Group LLC

Jane Street Group LLC increased its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 78.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 20,641 shares of the company’s stock after buying an additional 9,090 shares during the quarter. Jane Street Group LLC’s holdings in Spyre Therapeutics were worth $607,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of SYRE. Bank of New York Mellon Corp acquired a new stake in shares of Spyre Therapeutics in the second quarter valued at $2,767,000. Rhumbline Advisers acquired a new position in shares of Spyre Therapeutics in the 2nd quarter valued at $1,220,000. TD Asset Management Inc acquired a new position in shares of Spyre Therapeutics in the 2nd quarter valued at $827,000. Candriam S.C.A. acquired a new position in shares of Spyre Therapeutics in the 2nd quarter valued at $2,468,000. Finally, Quest Partners LLC acquired a new position in shares of Spyre Therapeutics in the 2nd quarter valued at $36,000. Institutional investors and hedge funds own 80.39% of the company’s stock.

Wall Street Analysts Forecast Growth

SYRE has been the subject of a number of recent analyst reports. Guggenheim increased their price target on Spyre Therapeutics from $50.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Wedbush reiterated an “outperform” rating and issued a $45.00 price target on shares of Spyre Therapeutics in a research report on Friday, November 8th. Finally, Robert W. Baird increased their price target on Spyre Therapeutics from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $51.50.

Spyre Therapeutics Trading Up 2.1 %

Shares of Spyre Therapeutics stock opened at $24.35 on Friday. The stock has a 50-day moving average price of $28.38 and a 200 day moving average price of $28.17. The company has a market cap of $1.25 billion, a P/E ratio of -3.26 and a beta of 2.82. Spyre Therapeutics, Inc. has a 1 year low of $20.07 and a 1 year high of $47.97.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).